<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38315011</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>05</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023.</ArticleTitle><Pagination><StartPage>e0383123</StartPage><MedlinePgn>e0383123</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e03831-23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.03831-23</ELocationID><Abstract><AbstractText Label="UNLABELLED">The SARS-CoV-2 XBB is a group of highly immune-evasive lineages of the Omicron variant of concern that emerged by recombining BA.2-descendent lineages and spread worldwide during 2023. In this study, we combine SARS-CoV-2 genomic data (<i>n =</i> 11,065 sequences) with epidemiological data of severe acute respiratory infection (SARI) cases collected in Brazil between October 2022 and July 2023 to reconstruct the space-time dynamics and epidemiologic impact of XBB dissemination in the country. Our analyses revealed that the introduction and local emergence of lineages carrying convergent mutations within the Spike protein, especially F486P, F456L, and L455F, propelled the spread of XBB* lineages in Brazil. The average relative instantaneous reproduction numbers of XBB* + F486P, XBB* + F486P + F456L, and XBB* + F486P + F456L + L455F lineages in Brazil were estimated to be 1.24, 1.33, and 1.48 higher than that of other co-circulating lineages (mainly BQ.1*/BE*), respectively. Despite such a growth advantage, the dissemination of these XBB* lineages had a reduced impact on Brazil's epidemiological scenario concerning previous Omicron subvariants. The peak number of SARI cases from SARS-CoV-2 during the XBB wave was approximately 90%, 80%, and 70% lower than that observed during the previous BA.1*, BA.5*, and BQ.1* waves, respectively. These findings revealed the emergence of multiple XBB lineages with progressively increasing growth advantage, yet with relatively limited epidemiological impact in Brazil throughout 2023. The XBB* + F486P + F456L + L455F lineages stand out for their heightened transmissibility, warranting close monitoring in the months ahead.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Brazil was one the most affected countries by the SARS-CoV-2 pandemic, with more than 700,000 deaths by mid-2023. This study reconstructs the dissemination of the virus in the country in the first half of 2023, a period characterized by the dissemination of descendants of XBB.1, a recombinant of Omicron BA.2 lineages evolved in late 2022. The analysis supports that XBB dissemination was marked by the continuous emergence of indigenous lineages bearing similar mutations in key sites of their Spike protein, a process followed by continuous increments in transmissibility, and without repercussions in the incidence of severe cases. Thus, the results suggest that the epidemiological impact of the spread of a SARS-CoV-2 variant is influenced by an intricate interplay of factors that extend beyond the virus's transmissibility alone. The study also underlines the need for SARS-CoV-2 genomic surveillance that allows the monitoring of its ever-shifting composition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arantes</LastName><ForeName>Ighor</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-4131-5338</Identifier><AffiliationInfo><Affiliation>Laboratório de Arbovírus e Vírus Hemorrágicos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grupo de Métodos Analíticos em Vigilância Epidemiológica, Fiocruz, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Kimihito</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>International Institute for Zoonosis Control, Hokkaido University, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarafim</LastName><ForeName>Sharbilla</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratório de Arbovírus e Vírus Hemorrágicos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gräf</LastName><ForeName>Tiago</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratório de Virologia Molecular, Instituto Carlos Chagas, Fiocruz, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyajima</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1347-4825</Identifier><AffiliationInfo><Affiliation>Fiocruz, Fortaleza, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khouri</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Instituto Gonçalo Moniz, Fiocruz, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Felipe Cotrim</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Departamento do Programa Nacional de Imunizações, Coordenação-Geral de Vigilância das doenças imunopreveníveis, Secretaria de Vigilância em saúde e ambiente, Brasília, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Almeida</LastName><ForeName>Walquiria Aparecida Ferreira</ForeName><Initials>WAF</Initials><AffiliationInfo><Affiliation>Departamento do Programa Nacional de Imunizações, Coordenação-Geral de Vigilância das doenças imunopreveníveis, Secretaria de Vigilância em saúde e ambiente, Brasília, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siqueira</LastName><ForeName>Marilda Mendonça</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resende</LastName><ForeName>Paola Cristina</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naveca</LastName><ForeName>Felipe Gomes</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Laboratório de Arbovírus e Vírus Hemorrágicos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Núcleo de Vigilância de Vírus Emergentes, Reemergentes ou Negligenciados, Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bello</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2724-2793</Identifier><AffiliationInfo><Affiliation>Laboratório de Arbovírus e Vírus Hemorrágicos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-19 Fiocruz Genomic Surveillance Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>E-26/202.896/2018</GrantID><Agency>Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)</Agency><Country /></Grant><Grant><GrantID>304883/2020-4</GrantID><Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)</Agency><Country /></Grant><Grant><GrantID>SEI-260003/019669/2022</GrantID><Agency>Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)</Agency><Country /></Grant><Grant><GrantID>306146/2017-7</GrantID><Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)</Agency><Country /></Grant><Grant><GrantID>313403/2018-0</GrantID><Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)</Agency><Country /></Grant><Grant><GrantID>311759/2022-0</GrantID><Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)</Agency><Country /></Grant><Grant><GrantID>MCTI402457/2020-0, 403276/2020-9, 423857/2021-5</GrantID><Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)</Agency><Country /></Grant><Grant><GrantID>VPPCB-005-FIO-20-2, VPPCB-007-FIO-18-2-30</GrantID><Agency>Fundação Oswaldo Cruz (FIOCRUZ)</Agency><Country /></Grant><Grant><GrantID>E26/210.196/2020, E-26/211.125/202</GrantID><Agency>Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)</Agency><Country /></Grant><Grant><GrantID>01.02.016301.00439/2023-70</GrantID><Agency>Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM)</Agency><Country /></Grant><Grant><GrantID>7200AA19CA00015</GrantID><Agency>United States Agency for International Development (USAID)</Agency><Country /></Grant><Grant><GrantID>002174</GrantID><Agency>HHS | Centers for Disease Control and Prevention (CDC)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brazil</Keyword><Keyword MajorTopicYN="N">SARI</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">XBB</Keyword><Keyword MajorTopicYN="N">phylogeography</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>5</Day><Hour>14</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>5</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38315011</ArticleId><ArticleId IdType="pmc">PMC10913747</ArticleId><ArticleId IdType="doi">10.1128/spectrum.03831-23</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Focosi D, Quiroga R, McConnell S, Johnson MC, Casadevall A. 2023. Convergent evolution in SARS-CoV-2 spike creates a variant soup from which new COVID-19 waves emerge. Int J Mol Sci 24:2264. doi:10.3390/ijms24032264</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24032264</ArticleId><ArticleId IdType="pmc">PMC9917121</ArticleId><ArticleId IdType="pubmed">36768588</ArticleId></ArticleIdList></Reference><Reference><Citation>Velavan TP, Ntoumi F, Kremsner PG, Lee SS, Meyer CG. 2023. Emergence and geographic dominance of omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges. Int J Infect Dis 128:307–309. doi:10.1016/j.ijid.2023.01.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.01.024</ArticleId><ArticleId IdType="pmc">PMC9850647</ArticleId><ArticleId IdType="pubmed">36681145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngiam JN, Al-Mubaarak A, Maurer-Stroh S, Tambyah PA. 2022. Does the COVID-19 XBB omicron subvariant signal the beginning of the end of the pandemic. SINGAPORE MED J 0:0. doi:10.4103/singaporemedj.SMJ-2022-180</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/singaporemedj.SMJ-2022-180</ArticleId><ArticleId IdType="pubmed">36648003</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh AXC, Chae S-R, Chiew CJ, Tang N, Pang D, Lin C, Tan KB, Lee VJ, Ho ZJM. 2023. Characteristics of the omicron XBB subvariant wave in Singapore. The Lancet 401:1261–1262. doi:10.1016/S0140-6736(23)00390-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00390-2</ArticleId><ArticleId IdType="pubmed">37061259</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Anraku Y, Nasser H, Shofa M, Oda Y, Lytras S, et al. . 2023. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two omicron subvariants. Nat Commun 14:2800. doi:10.1038/s41467-023-38435-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38435-3</ArticleId><ArticleId IdType="pmc">PMC10187524</ArticleId><ArticleId IdType="pubmed">37193706</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, Wang J, An R, Chen X, Zhang N, et al. . 2023. Imprinted SARS-CoV-2 humoral immunity induces convergent omicron RBD evolution. Nature 614:521–529. doi:10.1038/s41586-022-05644-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05644-7</ArticleId><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, Xie X, Shi P-Y. 2023. Low neutralization of SARS-CoV-2 omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med 29:344–347. doi:10.1038/s41591-022-02162-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02162-x</ArticleId><ArticleId IdType="pubmed">36473500</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora P, Cossmann A, Schulz SR, Ramos GM, Stankov MV, Jäck H-M, Behrens GMN, Pöhlmann S, Hoffmann M. 2023. Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage. Lancet Infect Dis 23:147–148. doi:10.1016/S1473-3099(22)00831-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00831-3</ArticleId><ArticleId IdType="pmc">PMC9815825</ArticleId><ArticleId IdType="pubmed">36620969</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijokaite-Guraliuc A, Das R, Zhou D, Ginn HM, Liu C, Duyvesteyn HME, Huo J, Nutalai R, Supasa P, Selvaraj M, et al. . 2023. Rapid escape of new SARS-CoV-2 omicron variants from BA.2-directed antibody responses. Cell Rep 42:112271. doi:10.1016/j.celrep.2023.112271</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112271</ArticleId><ArticleId IdType="pmc">PMC9988707</ArticleId><ArticleId IdType="pubmed">36995936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju B, Fan Q, Liu C, Shen S, Wang M, Guo H, Zhou B, Ge X, Zhang Z. 2023. Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination. Cell Rep 42:112532. doi:10.1016/j.celrep.2023.112532</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112532</ArticleId><ArticleId IdType="pmc">PMC10201307</ArticleId><ArticleId IdType="pubmed">37219999</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J, Hachmann NP, Collier A-R, Lasrado N, Mazurek CR, Patio RC, Powers O, Surve N, Theiler J, Korber B, Barouch DH. 2023. Substantial neutralization escape by SARS-CoV-2 omicron variants BQ.1.1 and XBB.1. N Engl J Med 388:662–664. doi:10.1056/NEJMc2214314</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214314</ArticleId><ArticleId IdType="pmc">PMC9878581</ArticleId><ArticleId IdType="pubmed">36652339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mykytyn AZ, Rosu ME, Kok A, Rissmann M, van Amerongen G, Geurtsvankessel C, de Vries RD, Munnink BBO, Smith DJ, Koopmans MPG, Lamers MM, Fouchier RAM, Haagmans BL. 2023. Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1. Lancet Microbe 4:e294–e295. doi:10.1016/S2666-5247(22)00384-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00384-6</ArticleId><ArticleId IdType="pmc">PMC9842387</ArticleId><ArticleId IdType="pubmed">36657480</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CY, Chiew CJ, Pang D, Lee VJ, Ong B, Lye DC, Tan KB. 2023. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. Lancet Infect Dis 23:799–805. doi:10.1016/S1473-3099(23)00060-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00060-9</ArticleId><ArticleId IdType="pmc">PMC10306341</ArticleId><ArticleId IdType="pubmed">36924786</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu K-L, Jiang X-L, Zhan B-D, Wang X-J, Xia X, Cao G-P, Sun W-K, Huang P-X, Zhang J-Z, Gao Y-L, Dai E-H, Gao H-X, Ma M-J. 2023. Durability of neutralization against omicron subvariants after vaccination and breakthrough infection. Cell Rep 42:112075. doi:10.1016/j.celrep.2023.112075</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112075</ArticleId><ArticleId IdType="pmc">PMC9906998</ArticleId><ArticleId IdType="pubmed">36774551</ArticleId></ArticleIdList></Reference><Reference><Citation>Akerman A, Milogiannakis V, Jean T, Esneau C, Silva MR, Ison T, Fichter C, Lopez JA, Chandra D, Naing Z, et al. . 2023. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. EBioMedicine 90:104545. doi:10.1016/j.ebiom.2023.104545</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104545</ArticleId><ArticleId IdType="pmc">PMC10060887</ArticleId><ArticleId IdType="pubmed">37002990</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Wu L, Xu Z, Wang X, Xie Y, Chai Y, Zheng A, Zhou J, Qiao S, Huang M, Shang G, Zhao X, Feng Y, Qi J, Gao GF, Wang Q. 2023. An updated atlas of antibody evasion by SARS-CoV-2 omicron sub-variants including BQ.1.1 and XBB. Cell Rep Med 4:100991. doi:10.1016/j.xcrm.2023.100991</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.100991</ArticleId><ArticleId IdType="pmc">PMC10027947</ArticleId><ArticleId IdType="pubmed">37019110</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraone JN, Qu P, Zheng Y-M, Carlin C, Jones D, Panchal AR, Saif LJ, Oltz EM, Gumina RJ, Liu S-L. 2023. Continued evasion of neutralizing antibody response by omicron XBB.1.16. Cell Rep 42:113193. doi:10.1016/j.celrep.2023.113193</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.113193</ArticleId><ArticleId IdType="pmc">PMC10872815</ArticleId><ArticleId IdType="pubmed">37777967</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M, Cooper D, Yang Q, Cai H, Muik A, Zhang Y, Lee D-Y, Şahin U, Anderson AS, Gruber WC, Xie X, Swanson KA, Shi P-Y. 2023. Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl J Med 388:854–857. doi:10.1056/NEJMc2214916</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214916</ArticleId><ArticleId IdType="pmc">PMC9891359</ArticleId><ArticleId IdType="pubmed">36734885</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, Porter-Morrison A, Hentenaar IT, Yamamoto F, Godbole S, Liu Y, Douek DC, Lee F-H, Rouphael N, Moreno A, Pinsky BA, Suthar MS. 2023. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster. N Engl J Med 388:183–185. doi:10.1056/NEJMc2214293</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214293</ArticleId><ArticleId IdType="pmc">PMC9812288</ArticleId><ArticleId IdType="pubmed">36546661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L, Ho DD. 2023. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186:279–286. doi:10.1016/j.cell.2022.12.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.12.018</ArticleId><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue C, Song W, Wang L, Jian F, Chen X, Gao F, Shen Z, Wang Y, Wang X, Cao Y. 2023. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis. 23, 278. 280. doi:10.1016/S1473-3099(23)00010-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00010-5</ArticleId><ArticleId IdType="pmc">PMC9897732</ArticleId><ArticleId IdType="pubmed">36746173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito J, Suzuki R, Uriu K, Itakura Y, Zahradnik J, Kimura KT, Deguchi S, Wang L, Lytras S, Tamura T, et al. . 2023. Convergent evolution of SARS-CoV-2 omicron subvariants leading to the emergence of BQ.1.1 variant. Nat Commun 14:2671. doi:10.1038/s41467-023-38188-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38188-z</ArticleId><ArticleId IdType="pmc">PMC10175283</ArticleId><ArticleId IdType="pubmed">37169744</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kikuchi T, Yotsuyanagi H, Halfmann PJ, Pekosz A, Kawaoka Y. 2023. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate. Lancet Infect Dis 23:402–403. doi:10.1016/S1473-3099(23)00070-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00070-1</ArticleId><ArticleId IdType="pmc">PMC9908083</ArticleId><ArticleId IdType="pubmed">36773622</ArticleId></ArticleIdList></Reference><Reference><Citation>Uriu K, Ito J, Zahradnik J, Fujita S, Kosugi Y, Schreiber G, Sato K. 2023. Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant. Lancet Infect Dis 23:280–281. doi:10.1016/S1473-3099(23)00051-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00051-8</ArticleId><ArticleId IdType="pmc">PMC9889095</ArticleId><ArticleId IdType="pubmed">36736338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Arora P, Nehlmeier I, Kempf A, Cossmann A, Schulz SR, Morillas Ramos G, Manthey LA, Jäck H-M, Behrens GMN, Pöhlmann S. 2023. Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5. Cell Mol Immunol 20:419–422. doi:10.1038/s41423-023-00988-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-023-00988-0</ArticleId><ArticleId IdType="pmc">PMC9982771</ArticleId><ArticleId IdType="pubmed">36869193</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu P, Faraone JN, Evans JP, Zheng Y-M, Carlin C, Anghelina M, Stevens P, Fernandez S, Jones D, Panchal AR, Saif LJ, Oltz EM, Zhang B, Zhou T, Xu K, Gumina RJ, Liu S-L. 2023. Enhanced evasion of neutralizing antibody response by omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Rep 42:112443. doi:10.1016/j.celrep.2023.112443</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112443</ArticleId><ArticleId IdType="pmc">PMC10279473</ArticleId><ArticleId IdType="pubmed">37104089</ArticleId></ArticleIdList></Reference><Reference><Citation>Addetia A, Piccoli L, Case JB, Park Y-J, Beltramello M, Guarino B, Dang H, de Melo GD, Pinto D, Sprouse K, et al. . 2023. Neutralization, effector function and immune imprinting of omicron variants. Nature 621:592–601. doi:10.1038/s41586-023-06487-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06487-6</ArticleId><ArticleId IdType="pmc">PMC10511321</ArticleId><ArticleId IdType="pubmed">37648855</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasoba D, Uriu K, Plianchaisuk A, Kosugi Y, Pan L, Zahradnik J, Ito J, Sato K. 2023. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant. Lancet Infect Dis 23:655–656. doi:10.1016/S1473-3099(23)00278-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00278-5</ArticleId><ArticleId IdType="pmc">PMC10156138</ArticleId><ArticleId IdType="pubmed">37148902</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehlmeier I, Kempf A, Arora P, Cossmann A, Dopfer-Jablonka A, Stankov MV, Schulz SR, Jäck H-M, Behrens GMN, Pöhlmann S, Hoffmann M. 2023. Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage. Cell Mol Immunol 20:969–971. doi:10.1038/s41423-023-01030-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-023-01030-z</ArticleId><ArticleId IdType="pmc">PMC10165563</ArticleId><ArticleId IdType="pubmed">37156807</ArticleId></ArticleIdList></Reference><Reference><Citation>
ECDC . 2023. ECDC Classifies XBB.1.5-like lineages with the amino acid change F456L as variants of interest following an increase in SARS-Cov-2 transmission in EU/EEA countries and abroad. https://www.ecdc.europa.eu/en/news-events/ecdc-classifies-xbb15-lineages-amino-acid-change-f456l-variants-interest-following#:~:text=ECDC%20classified%20XBB.,which%20were%20previously%20in%20circulation.</Citation></Reference><Reference><Citation>Kaku Y, Kosugi Y, Uriu K, Ito J, Hinay AA, Kuramochi J, Sadamasu K, Yoshimura K, Asakura H, Nagashima M, Sato K. 2023. Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5. Lancet Infect Dis 23:e395–e396. doi:10.1016/S1473-3099(23)00553-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00553-4</ArticleId><ArticleId IdType="pubmed">37708910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsujino S, Deguchi S, Nomai T, Padilla-Blanco M, Plianchaisuk A, Wang L, Begum MM, Uriu K, Mizuma K, Nao N, et al. . 2023. Virological characteristics of the SARS-CoV-2 omicron EG.5.1 variant. Cold Spring Harbor Laboratory. doi:10.1101/2023.10.19.563209</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.10.19.563209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Ye S-B, Zhou Z-J, Song A-L, Zhu X, Peng J-M, Liang R-M, Yang C-H, Yu X-W, Huang X, Yu J, Qiu Y, Ge X-Y. 2023. Key mutations in the spike protein of SARSCoV2 affecting neutralization resistance and viral internalization. J Med Virol 95:e28407. doi:10.1002/jmv.28407</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28407</ArticleId><ArticleId IdType="pmc">PMC9877909</ArticleId><ArticleId IdType="pubmed">36519597</ArticleId></ArticleIdList></Reference><Reference><Citation>Yisimayi A, Song W, Wang J, Jian F, Yu Y, Chen X, Xu Y, Yang S, Niu X, Xiao T, et al. . 2024. Repeated omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625:148–156. doi:10.1038/s41586-023-06753-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06753-7</ArticleId><ArticleId IdType="pmc">PMC10764275</ArticleId><ArticleId IdType="pubmed">37993710</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Kempf A, Nehlmeier I, Cossmann A, Dopfer-Jablonka A, Stankov MV, Schulz SR, Jäck H-M, Behrens GMN, Pöhlmann S, Hoffmann M. 2023. Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3. Lancet Infect Dis 23:e391–e392. doi:10.1016/S1473-3099(23)00547-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00547-9</ArticleId><ArticleId IdType="pubmed">37716358</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R, Manthei DM, Gordon A, Liu L, Ho DD. 2023. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect Dis 23:e397–e398. doi:10.1016/S1473-3099(23)00555-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00555-8</ArticleId><ArticleId IdType="pubmed">37708906</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO . 2023. EG.5 initial risk evaluation. https://www.who.int/docs/default-source/coronaviruse/eg5-risk-evaluation.pdf?sfvrsn=6e9690e0_4.</Citation></Reference><Reference><Citation>Dyer O. 2023. Covid-19: infections climb globally as EG.5 variant gains ground. BMJ 382:1900. doi:10.1136/bmj.p1900</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.p1900</ArticleId><ArticleId IdType="pubmed">37586736</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums DV. 2023. Editorial: a rapid global increase in COVID-19 is due to the emergence of the EG.5 (Eris) subvariant of omicron SARS-CoV-2. Med Sci Monit 29:e942244. doi:10.12659/MSM.942244</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.942244</ArticleId><ArticleId IdType="pmc">PMC10478578</ArticleId><ArticleId IdType="pubmed">37654205</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Nadeau S, Yared M, Voinov P, Xie N, Roemer C, Stadler T. 2022. CoV-spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants. Bioinformatics 38:1735–1737. doi:10.1093/bioinformatics/btab856</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btab856</ArticleId><ArticleId IdType="pmc">PMC8896605</ArticleId><ArticleId IdType="pubmed">34954792</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian F, Feng L, Yang S, Yu Y, Wang L, Song W, Yisimayi A, Chen X, Xu Y, Wang P, Yu L, Wang J, Liu L, Niu X, Wang J, Xiao T, An R, Wang Y, Gu Q, Shao F, Jin R, Shen Z, Wang Y, Wang X, Cao Y. 2023. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455–456 synergistically enhances antibody evasion and ACE2 binding. PLoS Pathog 19:e1011868. doi:10.1371/journal.ppat.1011868</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1011868</ArticleId><ArticleId IdType="pmc">PMC10766189</ArticleId><ArticleId IdType="pubmed">38117863</ArticleId></ArticleIdList></Reference><Reference><Citation>
FIOCRUZ . 2021. SARS-Cov-2 Genomic surveillance in Brazil. Available from: https://www.genomahcov.fiocruz.br/en/</Citation></Reference><Reference><Citation>Resende PC, Delatorre E, Gräf T, Mir D, Motta FC, Appolinario LR, da Paixão ACD, Mendonça AC da F, Ogrzewalska M, Caetano B, et al. . 2020. Evolutionary dynamics and dissemination pattern of the SARS-CoV-2 lineage B.1.1.33 during the early pandemic phase in Brazil. Front Microbiol 11:615280. doi:10.3389/fmicb.2020.615280</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.615280</ArticleId><ArticleId IdType="pmc">PMC7925893</ArticleId><ArticleId IdType="pubmed">33679622</ArticleId></ArticleIdList></Reference><Reference><Citation>Dezordi FZ, Neto A da S, Campos T de L, Jeronimo PMC, Aksenen CF, Almeida SP, Wallau GL. 2022. Viralflow: a versatile automated workflow for SARS-CoV-2 genome assembly, lineage assignment, mutations and intrahost variant detection. Viruses 14:217. doi:10.3390/v14020217</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14020217</ArticleId><ArticleId IdType="pmc">PMC8877152</ArticleId><ArticleId IdType="pubmed">35215811</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksamentov I, Roemer C, Hodcroft E, Neher R. 2021. Nextclade: clade assignment, mutation calling and quality control for viral genomes. JOSS 6:3773. doi:10.21105/joss.03773</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.03773</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, Colquhoun R, Ruis C, Abu-Dahab K, Taylor B, Yeats C, du Plessis L, Maloney D, Medd N, Attwood SW, Aanensen DM, Holmes EC, Pybus OG, Rambaut A. 2021. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol 7:veab064. doi:10.1093/ve/veab064</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veab064</ArticleId><ArticleId IdType="pmc">PMC8344591</ArticleId><ArticleId IdType="pubmed">34527285</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Jaroszewski L, Godzik A. 2001. Clustering of highly homologous sequences to reduce the size of large protein databases. Bioinformatics 17:282–283. doi:10.1093/bioinformatics/17.3.282</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/17.3.282</ArticleId><ArticleId IdType="pubmed">11294794</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh K, Rozewicki J, Yamada KD. 2019. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. Brief Bioinform 20:1160–1166. doi:10.1093/bib/bbx108</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbx108</ArticleId><ArticleId IdType="pmc">PMC6781576</ArticleId><ArticleId IdType="pubmed">28968734</ArticleId></ArticleIdList></Reference><Reference><Citation>Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, Lanfear R. 2020. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol 37:1530–1534. doi:10.1093/molbev/msaa015</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/msaa015</ArticleId><ArticleId IdType="pmc">PMC7182206</ArticleId><ArticleId IdType="pubmed">32011700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. 2017. Modelfinder: fast model selection for accurate phylogenetic estimates. Nat Methods 14:587–589. doi:10.1038/nmeth.4285</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4285</ArticleId><ArticleId IdType="pmc">PMC5453245</ArticleId><ArticleId IdType="pubmed">28481363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A, Lam TT, Max Carvalho L, Pybus OG. 2016. Exploring the temporal structure of heterochronous sequences using tempest (formerly path-o-gen). Virus Evol 2:vew007. doi:10.1093/ve/vew007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/vew007</ArticleId><ArticleId IdType="pmc">PMC4989882</ArticleId><ArticleId IdType="pubmed">27774300</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Lemey P, Baele G, Ayres DL, Drummond AJ, Rambaut A. 2018. Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. Virus Evol 4:vey016. doi:10.1093/ve/vey016</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/vey016</ArticleId><ArticleId IdType="pmc">PMC6007674</ArticleId><ArticleId IdType="pubmed">29942656</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond AJ, Rambaut A, Shapiro B, Pybus OG. 2005. Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol 22:1185–1192. doi:10.1093/molbev/msi103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/msi103</ArticleId><ArticleId IdType="pubmed">15703244</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemey P, Rambaut A, Drummond AJ, Suchard MA. 2009. Bayesian phylogeography finds its roots. PLoS Comput Biol 5:e1000520. doi:10.1371/journal.pcbi.1000520</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1000520</ArticleId><ArticleId IdType="pmc">PMC2740835</ArticleId><ArticleId IdType="pubmed">19779555</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. 2018. Posterior summarization in bayesian phylogenetics using tracer 1.7. Syst Biol 67:901–904. doi:10.1093/sysbio/syy032</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sysbio/syy032</ArticleId><ArticleId IdType="pmc">PMC6101584</ArticleId><ArticleId IdType="pubmed">29718447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L-G, Lam T-Y, Xu S, Dai Z, Zhou L, Feng T, Guo P, Dunn CW, Jones BR, Bradley T, Zhu H, Guan Y, Jiang Y, Yu G, Kumar S. 2020. Treeio: an R package for phylogenetic tree input and output with richly annotated and associated data. Mol Biol Evol 37:599–603. doi:10.1093/molbev/msz240</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/msz240</ArticleId><ArticleId IdType="pmc">PMC6993851</ArticleId><ArticleId IdType="pubmed">31633786</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G. 2020. Using ggtree to visualize data on tree‐like structures. Curr Protoc Bioinformatics 69:e96. doi:10.1002/cpbi.96</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpbi.96</ArticleId><ArticleId IdType="pubmed">32162851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Piantham C, Nishiura H. 2021. Predicted domination of variant delta of SARS-CoV-2 before Tokyo Olympic games, Japan. Euro Surveill. doi:10.1101/2021.06.12.21258835</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.12.21258835</ArticleId><ArticleId IdType="pmc">PMC8268651</ArticleId><ArticleId IdType="pubmed">34240695</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser C, Galvani A. 2007. Estimating individual and household reproduction numbers in an emerging epidemic. PLoS ONE 2:e758. doi:10.1371/journal.pone.0000758</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0000758</ArticleId><ArticleId IdType="pmc">PMC1950082</ArticleId><ArticleId IdType="pubmed">17712406</ArticleId></ArticleIdList></Reference><Reference><Citation>Piantham C, Ito K. 2022. Predicting the trajectory of replacements of SARS-CoV-2 variants using relative reproduction numbers. Viruses 14:2556. doi:10.3390/v14112556</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14112556</ArticleId><ArticleId IdType="pmc">PMC9697243</ArticleId><ArticleId IdType="pubmed">36423165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Piantham C, Nishiura H. 2022. Estimating relative generation times and relative reproduction numbers of Omicron BA.1 and BA.2 with respect to Delta in Denmark. Math Biosci Eng. doi:10.3934/mbe.2022418</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/mbe.2022418</ArticleId><ArticleId IdType="pubmed">35942746</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SW, Sun K, Abbott S, Sender R, Bar-On YM, Weitz JS, Funk S, Grenfell BT, Backer JA, Wallinga J, Viboud C, Dushoff J. 2023. Inferring the differences in incubation-period and generation-interval distributions of the delta and omicron variants of SARS-CoV-2. Proc Natl Acad Sci U S A 120:e2221887120. doi:10.1073/pnas.2221887120</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2221887120</ArticleId><ArticleId IdType="pmc">PMC10235974</ArticleId><ArticleId IdType="pubmed">37216529</ArticleId></ArticleIdList></Reference><Reference><Citation>Held L, Sabanés Bové D. 2020. Likelihood and Bayesian inference: With applications in biology and medicine. Springer Nature, Berlin, Heidelberg.</Citation></Reference><Reference><Citation>Qu P, Xu K, Faraone JN, Goodarzi N, Zheng Y-M, Carlin C, Bednash JS, Horowitz JC, Mallampalli RK, Saif LJ, Oltz EM, Jones D, Gumina RJ, Liu S-L. 2023. Immune evasion, infectivity, and Fusogenicity of SARS-Cov-2 BA.2.86 and flip variants. Cell. doi:10.1016/j.cell.2023.12.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.12.026</ArticleId><ArticleId IdType="pmc">PMC10872432</ArticleId><ArticleId IdType="pubmed">38194968</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CY, Chiew CJ, Pang D, Lee VJ, Ong B, Lye DC, Tan KB. 2023. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. Lancet Infect Dis 23:799–805. doi:10.1016/S1473-3099(23)00060-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00060-9</ArticleId><ArticleId IdType="pmc">PMC10306341</ArticleId><ArticleId IdType="pubmed">36924786</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha NK, Burke PC, Nowacki AS, Simon JF, Hagen A, Gordon SM. 2023. Effectiveness of the coronavirus disease 2019 bivalent vaccine. Open Forum Infect Dis 10:ofad209. doi:10.1093/ofid/ofad209</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad209</ArticleId><ArticleId IdType="pmc">PMC10234376</ArticleId><ArticleId IdType="pubmed">37274183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewnard JA, Hong V, Kim JS, Shaw SF, Lewin B, Takhar H, Lipsitch M, Tartof SY. 2023. Increased vaccine sensitivity of an emerging SARS-CoV-2 variant. Nat Commun 14:3854. doi:10.1038/s41467-023-39567-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39567-2</ArticleId><ArticleId IdType="pmc">PMC10310822</ArticleId><ArticleId IdType="pubmed">37386005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TY, Lim WF, Ang GY, Yu CY. 2023. Genomic surveillance of SARS-CoV-2 in Malaysia during the era of endemic COVID-19. Life (Basel) 13:1644. doi:10.3390/life13081644</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13081644</ArticleId><ArticleId IdType="pmc">PMC10455073</ArticleId><ArticleId IdType="pubmed">37629505</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein EY, Fall A, Norton JM, Eldesouki RE, Abdullah O, Han L, Yunker M, Mostafa HH. 2023. Severity outcomes associated with SARS-CoV-2 XBB variants, an observational analysis. J Clin Virol 165:105500. doi:10.1016/j.jcv.2023.105500</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2023.105500</ArticleId><ArticleId IdType="pmc">PMC10232717</ArticleId><ArticleId IdType="pubmed">37290254</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N, Barouch DH. 2023. SARS-CoV-2 hybrid immunity: the best of both worlds. J Infect Dis 228:1311–1313. doi:10.1093/infdis/jiad353</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad353</ArticleId><ArticleId IdType="pubmed">37592872</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC . 2023. Covid data tracker. Available from: https://covid.cdc.gov/covid-data-tracker/#trends‗weeklyhospitaladmissions‗select‗00</Citation></Reference><Reference><Citation>
GOV UK. 2023. England summary. Available from: https://coronavirus.data.gov.uk</Citation></Reference><Reference><Citation>Arantes I, Bello G, Nascimento V, Souza V, da Silva A, Silva D, Nascimento F, Mejía M, Brandão MJ, Gonçalves L, Silva G, da Costa CF, Abdalla L, Santos JH, Ramos TCA, Piantham C, Ito K, Siqueira MM, Resende PC, Wallau GL, Delatorre E, Gräf T, Naveca FG. 2023. Comparative epidemic expansion of SARS-CoV-2 variants delta and omicron in the Brazilian state of amazonas. Nat Commun 14:2048. doi:10.1038/s41467-023-37541-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37541-6</ArticleId><ArticleId IdType="pmc">PMC10089528</ArticleId><ArticleId IdType="pubmed">37041143</ArticleId></ArticleIdList></Reference><Reference><Citation>
Cao YR X. 2023. Available from: https://twitter.com/yunlong_cao/status/1714694253530804588</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>